InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,360.79
(
0.26%
)
US TECH 100
18,582.00
(
0.34%
)
Dow Jones
38,868.04
(
0.18%
)
Brent Oil
81.76
(
3.04%
)
Bitcoin
69,544.00
(
-0.16%
)
Post# of 252123
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119801
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 06/12/2014 5:36:05 PM

Thursday, June 12, 2014 5:36:05 PM

Post# of 252123
TEVA prevails against BMY in Baraclude patent case:

http://www.sec.gov/Archives/edgar/data/818686/000130901414000410/exhibit1.htm

As a result, generic Baraclude will presumably be on the US market soon. BMY’s annualized US sales of branded Baraclude (a drug for HBV) are about $350M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up